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INTRODUCTION 
Parenteral gold salts and D-penicillamine are drugs sometimes indicated for the 
treatment of definite or classical rheumatoid arthritis (RA) unresponsive to more conservative 
therapy. The results of controlled trials with these drugs in i9601 '2 and 19733, respectively, 
have established them as "second line" therapy for RA. These drugs are variously described an 
"remission inducing", "disease modifying", or "slow acting" agents,4 However, after as much as 
a quarter century of use in patients with RA, many rheurnetologists remain unconvinced that 
gold or D-penicillamine have long term "remission inducing" effects  on RA.5-9 Lipsky4 and 
Schreiber10 outlined the properties of "remission inducing" drugs and included their ability to 
reduce clinical and biochemical manifestations of RA and provide protection from erosion of 
joint interfaces. 
Several investigations with these drugs demonstrated reduced clinical and biochemical 
measures of disease activity.1 • 11 ~13 Empire Rheumatism C o u n c i l p r o v i d e d 
evidence from a mierodose versus standard dose trial of gold that six months of gold injections 
may reduce disease activity for up to 18 months in patients with RA. This study demonstrated 
significant improvement in functional grade, grip strength, erythrocyte sedimentation rate, and 
analgesic use in the standard dose gold group. Adverse reactions occurred twice as often with 
standard doses of gold. D-Pem'cillamine was compared to placebo in a study by the Multicentre 
Trial Group.3 Drug or placebo was given for 12 months. Drug treatment improved patient 
"well being", grip strength, and functional class, and reduced patients' pain, erythrocyte 
sedimentation rate, joint index, and morning stiffness.  Placebo caused fewer adverse reactions. 
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Although these placebo controlled trials and others11-14 demonstrated that 
D-penicillamine treatment or chrysotherapy may produce clinical benefit for 12 months or 24 
months, respectively, the concept that these drugs are "remission inducing" suggests that 
disease progression will be halted or slowed. Radiographic analysis has been used to assess 
prevention or slowing of joint erosion in RA treated with both parenteral gold and 
D-penicillamine. There is, however, disagreement among researchers whether gold provides 
protection from joint erosion.1-2,7,9,11,15,16
 T h e £ m p ) r 8 R h e u m a t j s m Council' -2 detected 
no differences  in radiographic findings between the microdose and standard dose gold groups. 
Sigler, et a l 1 1 , however, maintained injections for 24 months. Thirteen subjects received gold 
and 14 received placebo injections. These investigators demonstrated the rate of progression of 
joint erosions assessed by roentgenograms favored the gold treated group. No studies to date have 
shown D-penicillamine to prevent joint erosion7 '9 '1 5 - '6 Lipsky cautions that: "Even though 
these drugs cause improvement in many patients, the induction of total clinical remissions,,, is 
still a relatively rare event" 4 
The controlled studies which have established the utility of parenteral gold salts and 
D-penicillamine have been short term trials. Ruddy17 and others 4 , 6 have suggested that 
disease suppression may last for months or years with continued administration of these drugs. 
The data supporting such practices with second line anti-rheumatic drugs is far from 
conclusive. Reports of studies in which D-penicillamine or parenteral gold have been employed 
for longer than 12 or 24 months indicate that many subjects discontinued such therapy because 
of excessive toxicity or failure to continue improving from drug therapy. The Cooperating 
Clinics Committee14 attempted to extend the treatment duration from six months to 18 months, 
but were able to do so in only 6 of 68 subjects due to bothersome side effects  or lack of benefit 
from drug treatment. No differences  were noted between gold and placebo groups at 18 months. 
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Kean and Anastassaides'8 described a discontinuation rate of 201 due to eventual therapeutic 
failure after 24 months on gold. Rosenthal19 reported that patients remained on gold for up to 
five years only 6% of the time and continued D-penicillamine for five years in 165? of cases. 
Orindulis and McConkey6 found that therapy with gold or D-penicillamine was continued for up 
to 24 months in 141 and 311 of patients, respectively. Rothermich, et al 2 0 similarly found 
only 301 of patients continued to benefit from D-penicillamine after 40 months of follow up. 
In summary, the reports of efforts  to treat RA with gold or D-penicillamine for more 
than 24 months are few. The results of short-term controlled and long-term uncontrolled 
studies demonstrate that chrysotherapy and D-penicillamine provide symptomatic relief  in 
patients who tolerate this treatment. The unresolved question is whether these drugs, as they are 
currently used, are "remission inducing." Some authors suggest that long term, randomized, 
placebo controlled trials are needed to resolve this question.5 -7 
Although long-term placebo controlled studies are unlikely to be conducted due to 
economic and ethical considerations, such studies may be unwarranted for additional reasons. An 
assumption made by many investigators is that gold and D-penicillamine provide sufficient 
symptomatic benefit and are sufficiently  well tolerated that many patients will remain on either 
drug indefinitely. This assumption, if true, is consistent with the concept that these drugs alter 
the course of RA and may even be "remission inducing." If the assumption is false and patients 
who tolerate the induction phase of treatment do not remain on that drug indefinitely, the need to 
document "remission inducing" properties of these drugs becomes less compelling. If most 
patients who begin taking gold or D-penicillamine discontinue treatment because of toxicity or 
unacceptable efficacy  and then "cycle" through other second line drugs in a like manner over a 
period of years, the descriptor "remission inducing" may be misleading and does not describe the 
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actual benefit of these drugs in patients with RA. The objective of this retrospective chart 
review is to characterize the outcomes of patients with RA initiated on parenteral gold or 
D-penicillamine. 
MATERIALS AND METHODS 
A retrospective review was performed of the medical records( charts) of patients with 
rheumatoid arthritis who were treated in the Rheumatology- Clinic at the University Hospital, 
University of Utah. Patients included in this study were initiated on gold or D-penicillamine 
between 1972 and 1977. Treatment outcomes were characterized from the time of treatment 
initiation up to January, 198S. The proposal to conduct this chart review was approved by the 
University of Utah Institutional Review Board. 
Inclusion criteria: 
Clinic appointment books for the year 1977 were used to identify potential patients for 
inclusion into the study. Charts of patients seen by the three Division Rheumatoiogists during 
1977 were scanned to identify all patients with RA who were seen during this year. Patients 
from this sample were included in the analysis if the following criteria were met. 
1) Diagnosis of classical or definite RA by American Rheumatism Association (ARA) 
criteria. 
2) Diagnosis mate after age 18. 
3) Patients received gold injections or D-penicillamine for the first  time between 
1972 and 1977. 
4) Patients tolerated "induction" doses as described below: 
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a) A cumulative dose of 1OOQmg of parenteral gold during the first  six months of 
therapy. Or, 
b) D-PeniciUamine in daily doses of at least SOOmg reached within the first  six 
months of therapy. 
Patients were excluded from further  study if any of the following existed. 
1) Any exclusions for the diagnosis of RA. (ARA criteria) 
2) Any of the following diagnoses were present: 
a) Ankylosing spondylitis 
b) Mixed connective tissue disease 
c) Psoriatic arthritis 
d) Pseudogout 







Data were extracted from progress notes, laboratory records, hospital discharge 
summaries, insurance forms, and other pertinent records in each patient's chart. Information 
regarding patient demographics and disease characteristics was collected, entered on data 
collection forms (Appendix A) and coded for data entry purposes (Appendix B). This information 
included: age, sex, duration of disease, erythrocyte sedimentation rate (ESR), positive or 
negative rheumatoid factor,  and the patient's "functional activity level" at the time gold or 
D-penicillamine was started. Therapeutic measures in addition to gold and D-penicillamine were 
also recorded and inducted; daily dose of prednisone or prednisone equivalent and duration of use, 
therapeutic aids which were prescribed or used, and previous joint surgeries. 
Additional data collected included the beginning and termination dates of the patient's 
initial second line drug, beginning and termination dates for any subsequent courses of gild or 
D-penicillamine, and date of exit from the study. Reasons for exiting from the study were 
recorded and included: death, loss to followup, initiation of therapy with a cytotoxic or 
immunosupressive drugs (other than prednisone), or the patient was still receiving gold or 
D-penicillamine as of January, 1985. 
Reasons for withdrawal of each drug were determined and recorded. Other information 
collected each time drug withdrawal occurred or when patients exited from the study Included 
ESR, level of activity, prednisone dose, additional therapeutic aids prescribed, and subsequent 
joint surgeries, when available. 
Verifying data collected: 
The accuracy of data collection was verified by randomly selecting three of the study 
patients' charts and repeating the data collection process, The original and repeated data 
collection forms of these patients were compared and agreed on >.951 of items. In addition, data 
entry was verified by repeated visual inspections. 
Data analysis: 
The coded data were entered and stored for later analysis on the Department of Family 
and Community Medicine, Division of Biostatistics' Hewlett Packard 3000 computer. 
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Descriptive statistics were recorded and non-parametric statistical analyses were performed 
using the Statistical Package for Social Sciences, version 9.1 for the Hewlett Packard 3000. 
Chi-square analysis was used to compare nominal data including: sex, level of activity, presence 
of a positive or negative rheumatoid factor,  and numbers of aids or joint surgeries. The 
Mann-Whitney U test was applied to ordinal data such as ESR, durations, and prednisone doses. A 
p value less than 0.05 was considered significant. 
RESULTS 
A total of 2051 patients was seen in the Division of Rheumatology clinic during 1977. 
Chart review revealed 381 patients who met the criteria for definite or classical RA. 
Chrysotherapy was initiated in 73 of these patients and D-penicillamine was initiated in 33 
from 1972 through 1977. Thirty five patients who started on gold and 20 who started 
D-penicillamine tolerated an "induction" period and were included in this study. 
Pretreatment patient characteristics for these 55 patients are shown in Table 1. 
Pretreatmentor concurrent therapeutic measures used in these patients are described in Table 
2. Patients in the gold and D-penicillamine groups were similar with regard to age, sex, 
background corticosteroid therapy, and most measures of disease severity. The group of patients 
who initially received D-penicillamine had disease activity for 8.5 years compared to 5.5 years 
duration in the gold treated group (p<0.05). More patients treated with D-penicillamine were 
considered to have a limited or very limited "functional activity level", 75/5 compared to 43$ 
for the gold group (p<0,05) and more had joint surgeries previously, 508 compared to 17% 
in the gold group (p<0.05). No other differences  were detected. 
The outcomes of the initial course of gold in 35 patients and D-penicillamine in 20 
patients are shown in Table 3. Seven of these 55 patients were able to continue this initial 
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course of second line treatment. Five of 35 gold treated patients (141) and 2 of 20 
D-penicillamine patients (101) exited from the study while still receiving either drug. The 
mean durations of therapy prior to exiting from the study were 68 and 94 months, respectively. 
Four of the patients receiving gold and one receiving D-penicillamine died or were lost to follow 
up before January, 1985. Thus, two patients, one from each drug treatment group, were known 
to be still receiving their initial courses of second line treatment at the end of the study period. 
The duration of therapy in these two patients was 85 and 108 months, respectively. During gold 
or D-penicillamine treatment, other measures such as additional therapeutic aids, addition of 
prednisone, and/or joint surgeries were employed in six of the seven patients. 
The initial course of therapy was discontinued in 48 of 55 patients (871). Toxicity 
resulted in withdrawal of gold in 341 and D-penicillamine in 501 of these first  courses of 
treatment. Drug treatment was withdrawn after an average of 32 months for gold and 26 months 
for D-penicillamine. Inability to maintain the initial clinical benefit resulted in withdrawal in 
461 of the gold group and 151 of the D-penicillamine group after a mean of 18 and 63 months, 
respectively. Reasons for withdrawal were unclear, but no evidence of toxicity was noted, in the 
remaining 61 of gold patients after a mean treatment period of 11 months and 251 of 
D-penicillamine patients after a mean treatment period of 35 months. 
The 48 patients who discontinued initial courses of parenteral gold or D-penicillamine 
were followed to determine their fate regarding second line therapy for RA. The results are 
shown in Figure 1. Of the 48 patients who were unable to continue the initial course of second 
line therapy, 17 patients did not receive additional courses of gold or D-penicillamine during 
the study period. Alternative second line agents, such as cytotoxic or immunosupressive drugs, 
were the next treatment for ten of these patients. Five patients received methotrexate, three 
received azathioprine, and one patient each received chlorambucil and cyclophosphamide. The 
remaining seven patients died or were lost to followup shortly after the initial course of gold or 
D-penicillamine was withdrawn. 
Thirty-one patients received subsequent courses of gold or D-penicillamine. The 
outcomes of these subsequent courses of therapy are summarized in Table 4. Eight patients 
exited from the study while still receiving one of these drugs. Three patients were receiving a 
second trial of their initial therapy after a "washout period" ranging from 3 to 24 months. Five 
patients "crossed over" to the other therapy after a "washout period" ranging from 0 to 31 
months. Seven of these patients died or were lost to followup an average of 13 months after the 
second course was begun. One patient "crossed over" from D-penicillamine and had received gold 
for 56 months at the end of the study period. Prednisone was added to the drug regimens in 751 
of these eight patients during the second course of second line drug treatment 
Ten courses of gold and 26 courses of D-penicillamine were given to the 31 patients who 
received more than the initial course of treatment Drug therapy was discontinued for various 
reasons in 60$ of these courses of gold after a range of 1 to 12 months. Of the 26 courses of 
D-Penicillamine given, 841 were withdrawn after a range of 2 to 55 months. The 23 patients 
who had subsequent courses of chrysotherapy or D-penicillamine treatment withdrawn 
eventually exited from the study. Cytotoxic or immunosuppressive drugs were the next 
treatment steps for one third of these patients. Five patients were taking nonsteroidal 
anti-inflammatory drugs and/or prednisone and one patient was tolerating disease symptoms 
with no drug therapy. The remaining ten patients in this group died or were lost to followup. 
DISCUSSION 
This retrospective chart review was undertaken with the aim of including at least 100 
consecutive patients initiated on gold therapy and a similar number of patients initiated on 
D-penicillamine between 1974 and 1976. However, records of patient visits were not available 
prior to 1977. Consequently, all patients seen in clinic during 1977 were identified and these 
charts were reviewed to find patients initiated on gold or D-penicillamine between 1974 and 
1976. This chart reveiw revealed that a sample of 200 patients would not be eligible for 
inclusion and our recruitment period was extended in order that the resulting sample would 
exceed 50 patients. The resulting patient selection process produced one source of potential bias 
in the outcomes described in these patients. This selection process may have produced a sample 
with a higher rate of drug withdrawal than a sample of consecutive patients. A source of bias 
unrelated to the selection process is the absence of a matched control group. The faculty of the 
University of Utah Division of Rheumatology believed that a comparable group of patients not 
receiving second line drugs, if they could be identified, would eventually "cross over" into a drug 
treatment group, making comparisons impossible. There were, however, several important 
observations made after studying this patient sample which help to describe the course of second 
line drug therapy in patients with RA. 
Parenteral gold and D-penicillamine have been shown to produce improvement in some 
manifestations of RA, in several controlled and uncontrolled s t u d i e s . 1 -15,18,20,21 
Although these drugs are sometimes referred  to as "remission Inducing", the evidence to support 
this label is inconclusive.^ Some investigators suggest that long term, placebo controlled 
trials are needed to demonstrate these "remission inducing" properties.5,7 The prerequisite to 
conducting such long term studies Is to demonstrate that substantial numbers of patients remain 
on these drugs for extended periods of time. The objective of this study was to characterize 
outcomes of patients started on gold or D-penicillamine. Fifty-five  patients were identified who 
started gold or D-penicillamine treatment between 1972 and 1977 and tolerated such treatment 
for at least six months. The sample size was limited by several factors. First, all patients 
started on gold or D-penicillamine during the time period of this study could not be identified. 
Second, a conservative approach to second line treatment resulted in less than 30$ of patients 
with RA identified in this study being initiated on gold or D-penicillamine. Finally, less than 
SOS of patients Initiated on one of these drugs was eligible for followup in this study because of 
the high rate of drug intolerance observed during the "induction" period, Treatment outcomes 
of these patients were followed for up to 12 years. Differences  between patients started on gold 
and D-penicillamine existed initially but there was no evidence that these groups fared 
differently  through the study period. 
Drug withdrawal was the outcome of initial courses of gold and D-penicillamine 
treatment in 871 of the patients included in this study. This rate of drug discontinuance is 
higher than some reports of gold or D-penicillamine withdrawal in the 
literature,314318,19,21 -24 One explanation for the high rate of drug withdrawal in this 
study is the length of follow up. Few reports in the literature followed patients for more than 
24 months. However, Rosenthal'9 found that 841 of patients discontinued gold and 94£ 
discontinued D-penicillamine after five years. Many patients in the present study had drug 
therapy withdrawn after more than 24 months. Table 3 summarizes the reasons for drug 
withdrawal in these initial courses of second line treatment If reasons for withdrawal are 
considered independently for each drug, the rate of drug discontinuance from toxicity is 
consistent with findings of Rothermich et al^ O .22
 a n ( j other Investigators.^1®'' ' ^ These 
drugs have been reported to provide improvement early but later be withdrawn from many 
patients because improvement does not continue or the disease progresses.16,20,24 The 
reasons for discontinuing gold and D-penicillamine in some patients were unclear, but none of 
these patients had evidence of toxicity recorded in their charts. It is reasonable to suspect that 
therapy was withdrawn from most of these patients because continued benefit was not seen. The 
frequency of drug withdrawal due to lack of continued benefit in patients whose records were 
reviewed, even when those with unclear reasons are included, is within the range reported by 
Q^epS_6,18,19,21,22,24 
Thus, efforts  to give gold or D-penicillamine to patients indefinitely are hampered by 
the necessity to discontinue treatment for a variety of reasons. The actual rate of withdrawal 
may exceed 871, as observed in this study. The duration of therapy in the four patients who died 
or were lost to follow up during the initial course of gold when they exited from the stud/ was as 
short as 20 months. When this duration of therapy is compared to that of the other patients, it is 
likely that some of these four patients eventually discontinued therapy. It is, therefore,  possible 
that the long term withdrawal rate for these drugs actually approaches 1001, Thus, few 
patients started on a second line drug will remain on that drug indefinitely. Consequently, 
long-term controlled trials designed to characterize "remission inducing" properties of gold or 
D-penicillamine are unlikely to be successful. 
Death and loss to follow up were frequently reasons for exiting from this study. Of the 
seven patients who exited from the study on the initial course of gold or D-penicillamine, two 
died during the followup period and three were lost to followup. Scott, et al 2 5 reported that 
deaths occurred in 151 of patients with RA during a ten year study. The upper age of patients in 
the present study, 77 years of age, and the advanced age of patients in other s tud ies1 - 3 '6 '2 1 
makes death an inevitable patient outcome for long term studies. Imposing upper age limits on 
patients included in studies and reducing the percentage of patients lost to followup would reduce 
the total enrollment needed to complete a long-term trial. Even if these reasons for exiting from 
a study were eliminated, a minimum of 1540 patients would have to be enrolled at the beginning 
of the study to produce a sample of 100 patients to evaluate when the study was completed. This 
size sample would present economic and pragmatic difficulties,  even for multi-center research 
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groups. 
The duration of treatment prior to exiting from the study ranged from 20 to 108 months 
in the seven patients who remained on initial courses of gold or D-penicillamine. The ability of 
these patients to remain on one of these drugs suggests that their RA was at least under control 
and possibly in "remission." However, six of these patients required the addition of prednisone, 
joint surgeries, and/or additional therapeutic aids to help control disease symptoms and 
progression during this time. The use of these additional measures suggests that, although gold or 
D-penicillamine provided symptomatic Improvement, neither therapy induced or maintained 
"remission" despite continued use in these patients. Kean and Anastassaides18 demonstrated 
"remission" (no active joints and no extra-articular findings) after 48 months of treatment in 
only 4 of 100 patients. In contrast, Srinivasan, et al^ reported that 73$ of patients who 
received gold for more than 18 months were in "remission"(no pain, stiffness,  or swelling). 
Goldberg, et al 2 6 indicated that 62$ of patients who tolerated therapy, continued to receive 
gold injections for an average of eight years. They'were unable, however, to find any objective 
evidence for disease "remission" or continued benefit in these patients. A uniform definition of 
"remission" has not been used by investigators and this contributes to the discrepancy in 
reported remission rates, as do differences  in the length of followup periods. Using global 
measurements of outcome, such as the intent to continue treatment in the absence of toxicity and 
use of additional therapeutic interventions, the findings in this study fail to support the premise 
that either gold or D-penicillamine is predictably "remission inducing." 
It has been suggested that practitioners use second line agents with the "intent to treat" 
patients for as long as some benefit is seen.4 '6 '^ Our data indicate that this "intention" is 
overridden by several factors in many patients initiated on gold or D-penicillamine. Puller and 
Capell 5 suggested that the availability of alternative second line agents may strongly reduce the 
desire to maintain a patient on a toxic medication if it is producing questionable results. One 
approach to second line drug therapy is to use a drug for as long as possible, but substitute 
another second line agent if toxicity develops or the patient no longer benefits from the initial 
drug. The sequential use of gold followed by D-penicillamine has been examined. 27-29
 T h e s e 
researchers have concluded that in most cases gold and D-penicillamine behave independently 
with respect to who responds to therapy or develops toxicity, Evers and Sundstrom 3 0 described 
23 patients who received a repeated course of parenteral gold therapy after the first  course was 
discontinued for various reasons. They found that only 171 of subjects were able to remain on 
the second course for up to 24 months. The followup period in the previous studies was short and 
outcomes of these subsequent courses were not characterized. Sequential use of second line 
agents was apparent in the present stud/. Two or more courses of gold and/or D-penicillamine 
were given to 561 of patients and 131 of patients received three or four courses of gold and/or 
D-penicillamine. A small number of patients received repeated courses of the same drug.lf  using 
gold and D-penicillamine sequentially is useful, perhaps some patients will continue receiving a 
subsequent course of these drugs indefinitely. Eight of 31 patients were still receiving the 
second course of second line treatment when they exited from the present study. Table 4 shows 
that the duration of these subsequent courses was one to 56 months. It is likely that drug 
withdrawal would continue to occur if followup of these patients was maintained. 
The initial and/or subsequent courses of gold or D-penicillamine were not able to be 
continued in 40 of 55 patients. Seventeen patients had "cycled through" gold and 
D-penicillamine treatment and were receiving the alternative second line agents methotrexate, 
azathioprine or chlorambucil when they exited from the study. Two patients exited from the 
study because chlorambucil was started but subsequently "cycled" beck onto D-penicillamine 
only to receive another course of chlorambucil. Data from the present study, and from 
others2 7"3 0 provide evidence that this "cycling" phenomenon ocourrs with some frequency, 
but no reports have been published which characterize the benefit of "cycling" patients through 
multiple second line drugs, Lorenzen8 proposed that new approaches were needed to find the 
most appropriate way to use available agents. Efforts  should be directed toward characterizing 
the "cycling" phenomenon and determining if acceptable change in disease occurs when second 
line drugs are used in this manner. If "cycling" of second line agents is useful, the best duration 
for each "cycle" should be determined, If this approach to treatment proves to be unsatisfactory 
in patients with RA, the use of combination drug regimens, as explored by Bitter31, and efforts 
directed at developing and testing new drugs which may have "remission Inducing" properties 
should be more aggressively pursued. 
Kirwan and Currey 7 have summarized the need for conducting long term, placebo 
controlled studies with existing second line agents for RA. Pullar and Capell 5 agree with the 
need, but caution that such studies cannot be conducted using conventional methodologies, The 
findings of the present study suggest that high rates of drug withdrawal and patient attrition will 
be serious methodological concerns in designing such studies. Additionally, there is no evidence 
from available data that these drugs, as currently used, are "remission inducing." Patients with 
RA may expect, when told that gold and D-penlclllamlne are "remission inducing", that their 
disease will remit after starting treatment with these drugs, Outcomes of second line treatment 
in the present stud/ suggest that patients slowly "cycle through" drugs like gold and 
D-pen1c1llamme, and other therapeutic measures frequently become necessary to control 
manifestations of RA, Patients will better appreciate the benefits of drug therapy for RA when 
practitioners describe gold and D-penicillamine in terms of expected outcomes rather than in 
terms of hoped for outcomes, 
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SUMMARY 
The treatment outcomes in 55 patients with definite or classical RA initiated on 
chrysotherapy or D-penicillamine were characterized over a 7 to 12 year period. Seven 
patients (131) were still receiving their initial course of parenteral gold or D-penicillamine 
at the time of exiting from the study. The remaining 48 patients had initial courses of second 
line drugs withdrawn for various reasons. Thirty-one patients received subsequent courses of 
gold or D-penicillamine. Eight of these patients were receiving that drug when they exited from 
the study. Patients who remained on these drugs often required additional measures to control 
their disease, suggesting that remission is not a predictable outcome in patients able to continue 
these drugs indefinitely. A large number of patients died or were lost to followup during the 
study period. Many patients "cycled through" several second line drugs. These findings challenge 
the feasibility of conducting long term trials with gold and D-penicillamine to characterize 
"remission inducing" properties in RA. Future research efforts  should be directed toward new 
ways to use existing drugs as well as developing new drugs to use for RA. 
TABLES 
IB 
Table 1: Petient characteristics of 55 patients init iated on 
and tolerating at least six months of chrysotherapy 
or D-penicillamine treatment. 
Treatment group 
Characteristics Chrysotherapy D-penicillamine 
Number of pts. 35 20 





















47.5± 25 50.9+ 27 
Functional 
Act iv i ty level 
Normal 
Limited 




5 * * 
1 1 
4 
Age, duration, and ESR are mean ± standard deviation 
* p<0.05 (Mann-Whitney U) 
* * Ch i 2 = 6.203 p<0.05 
19 
Table 2: Therapeutic measures used previously or 
concurrently in patients init iated on and 
tolerating six months of chrysotherapy or 
D-penicillamine treatment. 
Therapeutic Treatment group 
measure Chrysotherapy D-penicillamine 
Patients in group 35 20 
Prednisone therapy 
duration of use 
range(months) 1-96 1-99 
daily dose(mode) 7.5 7.5 
(mg/day ) 
number of pts. 1 1 ! 1 
Therapeutic aids 
total aids 7 19 
in group 
pts. using 7 8 
Joint surgeries 
total suraeries 10 22 
in group 
pts. receiving 6 10 * 
* Ch i 2 = 4.62 p<0.05 
Table 3: Treatment outcomes of the in i t ia l course of 
chrysotherapy or D-penicillamine treatment 
in 55 patients. 
Treatment Treatment group 
outcome Chrysotherapy D-penicillamine 
Number of courses 35 20 
Drug continued at 
exit from study 
n (58) 5 (14.3) 2(10) 
mean duration 68.4 mas. 94.0 mos. 
of treatment 
range (months) 20-96 80-108 
exited due to 
death or loss 
to followup 




n (5g) 12 (34.4) 10 (50) 
mean duration 3 1.6 mos. 26,0 mos 
of treatment 
range (months) 8-79 7-72 
Loss of efficacy 
n (%) 16 (45.7) 3 (15) 
mean duration 18.4 mos. 62.7 mos. 
of treatment 
range (months) 7-73 26-109 
Reasons unclear 
n (%) 2 (5.7) 5 (25) 
mean duration 1 1.5 mos. 35.0 mos. 
of treatment 
range (months) 1 1-12 12-66 
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Table 4; Treatment outcomes of subsequent courses of 
chrysotherapy or D-penicillamine treatment 
in 31 patients. 
Treatment Subsequent treatment 
outcome Chrysotherapy D-penicillamine 
Number of courses 10 26 
Drug continued at 
exit from study: 
number of pts. 4 4 
% of courses 40.OS 15.4% 
mean duration 20,0 mos, 1 7.3 mos. 
of treatment 
range (months) 1-56 1-43 
exited due to 
death or loss 
to followup 




% of courses 20,0% 53.8% 
mean duration 1,5 mos. 0.7 mos. 
of treatment 
range (months) 1-2 2-28 
Loss of efficacy 
% of courses 20.OS 11.5 % 
mean duration 1 1.5 mos. 24.0 mos. 
of treatment 
range (months) 11-12 15-35 
Reasons unclear 
% of courses 20.0^ 19,21 
mean duration 8.5 mos. 39.0 mos; 
of treatment 
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Arthritis Chart Review: Second Line Drugs Page Number 
CJS006 PatientNumber. 
Id Number 00 
Card Number • • 
Baseline information: 
A. Patient Information 
1) Age at entry (years) OD 
2) Sex 1 =male 2= female 0 
3) Duration of disease before entry (yr) • • 
4) Date first  gold or d-pen started • • / • • 
(filler spaces) • • • • • • • • • • 
5) Duration of oral corticosteroid use prior to entry (months) DID 
B. Disease Information 
1) Disability 
a) Aids Rx'd Total number (incl. others not listed below) 00 
1 = present Wheelchair • 
2= absent Walker 0 
Cane • 
b) Prior joint surgeries; total number 00 
c) Vocational/activity level • 
1 = normal (Full ROM,stand,bend,reach,full  time work) 
2= limited (Limited ROM .sitting,no reaching,part time work) 
3= very limited( Very limited ROM .sitting,bedridden,no work) 
4= notevaluable 
2) Laboratory (place 9's if not available) 
a) E.S.R. mm/hr • • • 
b) Rh factor 1 = +, positive 2= - , negative 0 
c) Hgb gm/dl 00 
d) Hct % on 
e) Platelets */mm5 000 
C. Background corticosteroids 
1) Mode daily dose prior to entry (prednisone equivalents,rng) 00,0 
Tabulate doses here to determine mode: 
D, Admitting M.D. 1 =Ward 2=Samuelson 3=Wi!liams 0 
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Arthritis Chart Review; Second Line Drugs 
CJSQ06 
Pap Number 
Id Number • • 
Card Number • • 
Followup data 
A. Drug information 
1) Sequential drug treatment step (mark * 1,2,3,4,5,6,etc.) • • 
a) Is this the exit step of treatment? 1 =yes 2=no 0 
b) Drug used: 1 = gold, 2= d-penicillamine, 3= hydroxychloro- 0 
quine, 4= no drug for >8 weeks, 5= other (see instructions). ( • ) 
c) Drug started/discontinued on (mo/yr) •O/DOtoOO/OO 
or (exited study on) 
d) Dose when discontinued (tabulate in margin) • • • • • 
i) Gold (a above= 1; total cumulative dose) mg or 
ii) D-pen or hydroxychloro:(aabove=2or3;fiaily  dose at d/c)mg 
2) Reason for discontinuance • 
1 = Toxicity , 2= Lack of benefit from treatment, 
3= Other/unknown, 4= not d/c'dCexit treatment) 
a) if d=l; list type of toxicity 0 
1 = dermal ,2= renal ,3= hematologic,4= ocular ,5= other 
b) if d=2 ; list evidence • 
1 = clinically worse,2= laboratory worse,3=both I and 2 
B. Disease information 
1) Aids ( total cumulative * at discontinuance) 00 
Mark specific aids at exit visit only Wheelchair • 1 = prescribed 2=not prescribed Walker 0 
Cane • 2) Surgeries (total cumulative to date) 00 
3) Vocational/ Activity level at discontinuance D 
4) Labs at discontinuance 
ESR mm/hr 000 
(place 9's if not available) Rh factor 1=* 2=- 0 
Hgb gm/dl 00 
Hct % 00 
(Tab.steroid doses above) Pits */mm3 000 
5) Background steroids (mode daily dose during period, = to pred.) 00.0 
6) Responsible M.D. 1 =Ward 2= Samueison 3=Williams 0 
APPENDIX B 
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Arthritis Chart Review: Second Line Drugs 
CJSQ06 
Instructions for "coding" specific questions. 
1) General; When information is not available place 999... in the boxes. 
2) Question B.l,a. AidsRx'd 
a) "others" includes any device or aid prescribed for use by the patient to relieve discomfort 
or make daily activities easier to accomplish. 
b) In addition to wheelchair, cane, or walker this could include but not be limited to: toilet 
seats, cervical pillows, shoes, splints, braces, etc. 
3) Question B. 1 .c. Vocational/activity level. 
a) The vocational/ activity levels are determined as follows. "Normal" indicates that patient 
has normal ranp of motion on physical examination, able to perform all daily 
activities with little limitation and/or able to work full time."Limited" indicates that 
the patient has some limits of range of motion on physical examination, daily 
activities are limited and/or are able to work part time only due to physical 
limitations. "Very limited" indicates the patient has gross limits on physical exam, is 
or is nearly bedridden/ housebound, and/or unable to work due to physical 
limitations. Findings used to make this evaluation include: Disability claims vs 
employment status, activity described in the chart, joint and R.G.M. assessments, 
hospital discharge summariies, eta 
4} Followup data question A. 1 .a. Exit step? 
a) Choice 1 or yes applies only if all courses of gold and/or D-penicillamine have been 
discontinued. This step automatically becomes "yes" if the patient is placed on 
cytotoxic drugs or azathioprine. If the patient drops out before a particular second 
line therapy is discontinued this box in marked 2 and the next page becomes the exit 
step with the "Drug used" marked "lost to followup". 
5) Followup data question A. I.b. Drug used? 
a) Choice 5 applies to the exit step of the sequence. The choices that can apply to the box 
"(•)" are: 
1) Background therapy only, NSAID and/or corticosteroid =0 
2) No drug therapy = 1 
3) Death = 2 
4) Lost to followup, moved, etc. = 3 
5) Methotrexate = 4 
6) Chlorambucil = 5 
7) Cyclophosphamide = 6 
8) Azathioprine » 7 
9) Exited on second-line therapy, continues to be followed = 8 
10) Not exit step = 9 
6) Followup data question A.2.b. 
a) "Clinically worse" can mean clinically worse, or no change in clinical activity, or no 
benefit from therapy. 
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